LATEST NEWS
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations

Radioenhancing Hafnium Oxide Nanoparticles (NBTXR3) Followed by SBRT in Patients With Hepatocellular Carcinoma and Liver Metastases (NBTXR3-103): Phase 1 Dose-Escalation Trial

View Resource PDF
View Resource

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.

CONTACT US